MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL
VIRTUAL MEETING
June 22, 2026
Minutes

Agenda Item 1

Call to Order:
Co-Chair Lorriane Diana called the meeting to order at 2:02 PM.

(Roll Call) Stakeholder Council Members Present:
Pallavi Arora, Shawn Brown, Angela Bryant, Lorraine Diana, Robert Embry, Dr. John Gambrill, Candace Hall, Dr. Sherita Golden, Jim Gutman, Marc Nicole, Shaun O'Brien, Mandy Poplowski, Amy Prentice, Monica Elise Proctor Wilson, Kimberly Robinson, Glenn Schneider, Kelly Schultz, Joseph Winn

Agenda Item 2

April 27, 2026 Meeting Minutes
Co-Chair Diana asked for a motion to approve the April 27, 2026 meeting minutes. Jim Gutman made the motion and was seconded by Shaun O'Brien.

Agenda Item 3

Opportunity for Public Comment
The PDASC did not receive any written comments and there were no requests for oral public comment.

Agenda Item 4

Update on Ongoing Cost Review Studies
Christina Shaklee provided a short verbal update on the Cost Review Study process. Ms. Shaklee stated the following:

- The Board has approved proposed Upper Payment Limit regulations for Jardiance and Ozempic. Those regulations will go through the APA process and should be in an upcoming DSD register for a 30 day comment period.
- COMAR 14.01.06 Implementation and Monitoring of Upper Payment Limits were published in the June 12, 2026 DSD Maryland Register and comments are being accepted until July 13, 2026.
- Staff is planning to close out Trulicity, Dupixent, and Skyrizi by the end of this year.

Agenda Item 5

Cost Review Study Process and Policy Review Process Regulations
Co-Chair Diana explained the purpose of agenda item five and the PDASC opportunities to weigh in on the Cost Review Study Process Regulations to date. The purpose of this discussion is to gather input from the stakeholder council regarding the cost review study process (COMAR 14.01.04.01, et seq.).

Ms. Shaklee presented the draft proposed cost review study process regulation changes to date. Ms. Shaklee reviewed feedback from previous PDASC meetings, informational hearings, and comment letters. The PDASC were then asked to discuss the following questions in regards to the draft proposed Cost Review Study Process Regulations (COMAR 14.01.04.01):

- Are there additional changes to the draft regulations that should be considered?
- Beyond the current draft, are there specific items that remain unclear?
- Any additional questions or considerations?

One member requested to discuss agenda items pertaining to the June 30, 2026 PDAB meeting. It was requested that we hold on that discussion until agenda item five is concluded.
There was a short discussion around patient access programs and eligible government entities. The presentation is posted on the stakeholder page of the PDAB website.

Agenda Item 6

New Business
Co-Chair Lorraine and Co-Chair Nicole utilized their prerogative to add agenda item six, "New Business," to this agenda.

The PDASC discussed a question from a member regarding the 340B legislative report that will be discussed at the June 30, 2026 PDAB meeting. Staff explained that the 340B report is a legislatively mandated report, due July 1, 2026, that asked the PDAB to study the scope and implementation of the 340B program in Maryland, application of the policy, and a description of how 340B entities are using the resources accrued. The report contains the Board's findings including data from a data request that the PDAB solicited from the 340B entities. The 340B report will be posted prior to the June 30, 2026 meeting and will be subject to a vote at the next Board meeting.

Agenda Item 7

Administrative Update

- The PDASC currently has five appointment vacancies. Staff is working diligently with the appointing offices to get those filled as soon as possible.

Agenda Item 8

Co-Chair's Update

- The next regularly scheduled PDASC Meeting is on August 24, 2026. Staff is continuing to work on a hybrid meeting later in the year.

Agenda Item 9

Adjournment
Co-Chair Nicole thanked everyone for attending the meeting and asked for a motion to adjourn the meeting. Shaun O'Brien made the motion which was seconded by Robert Embry.
Adjourned at 2:36 PM.